Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic Biosciences (PBL), the UK subsidiary of ProMetic Life Sciences, has signed an agreement with a European biotechnology manufacturing company to develop an affinity resin product and its related manufacturing process.
Subscribe to our email newsletter
Under the agreement, ProMetic will receive $1.4m and the client will be provided with a biosimilar product.
PBL chief executive officer Steve Burton said the company’s technology allows it to custom design affinity products according to each client’s specific needs, providing them with high-performance manufacturing processes and lower cost biological products.
"Furthermore, the application of our novel purification technology enables biosimilar manufacturers to avoid existing intellectual property developed and used for production of the original products and to generate new intellectual property around the new process which provides them with a competitive advantage" added Burton.